Pathology of Chronic Hepatitis C in Children: Peds-C Trial

2008-07-31 20:15:54

Pathology of Chronic Hepatitis C in Children: Peds-C Trial
While the natural history of chronic hepatitis C virus (HCV) infection has been
well studied in adults, less is known about how the disease progresses in
children.
In an analysis described in the March 2008 issue of Hepatology, investigators
evaluated liver histopathology among children with chronic hepatitis C
participating in the Peds-C trial, which assessed the safety and efficacy of
pegylated interferon alfa-2a (Pegasys) plus ribavirin in pediatric patients.
The present analysis involved liver biopsies from 121 previously untreated
children ages 2 to 16 years (mean 9.8 years). Participants had no other
identifiable causes of liver disease besides HCV infection, no signs of hepatic
decompensation, and no other significant non-hepatic disease. Liver biopsies
were scored for inflammation, fibrosis, steatosis (fat accumulation), and other
histological features.
Results
. Liver inflammation was minimal in 42% of the biopsy samples, mild in 17%,
moderate in 38%, and severe in 3%.
. 5 patients had bridging fibrosis and 2 had cirrhosis.
. 56% of samples showed no liver steatosis, 34% showed minimal steatosis, and
10% showed mild steatosis; there were no cases of moderate or severe steatosis.
. Inflammation scores correlated with fibrosis scores, serum alanine
aminotransferase (ALT) levels, and duration of HCV infection.
. However, inflammation was not associated with patient age, body mass index
(BMI), or HCV genotype.
. Fibrosis scores correlated with inflammation, but not with age, HCV
genotype, BMI, or steatosis.
. Steatosis correlated with ALT levels and BMI, with overweight children
having more fibrosis than those who were not overweight.
Conclusion
In conclusion, the authors wrote, "in this cohort of HCV-infected children,
inflammation, fibrosis, and steatosis were milder than reported for
treatment-naive adults with chronic hepatitis C, but there were several with
bridging fibrosis or cirrhosis."
They added that, "The positive correlation of inflammation with duration of
infection and fibrosis, and of obesity with fibrosis suggest that children with
chronic hepatitis C will be at risk for progressive liver disease as they age
and possibly acquire other comorbid risk factors."
3/14/08
Reference
ZD Goodman, HR Makhlouf, L Liu, and others. Pathology of chronic hepatitis C in
children: Liver biopsy findings in the Peds-C Trial. Hepatology 47(3): 836-843.
March 2008.
http://www.hivandhepatitis.com/hep_c/news/2008/031408_a.html

Another good video!

2008-07-31 17:18:39

Health Matters: All About Hepatitis
http://www.youtube.com/watch?v=1bLzaOULKso
Hepatitis C is a growing public health problem nearing epidemic proportions.
John G. McHutchison, M.D. discusses the many forms of Hepatitis, who is at risk
and what treatments are currently available.
Series: "Health Matters" [11/2000] [Health and Medicine] [Show ID: 5150]

Kevorkian Plans Congressional Run

2008-07-31 15:08:26

Kevorkian Plans Congressional Run
By KEN THOMAS
WASHINGTON (AP) - Assisted-suicide advocate Jack Kevorkian plans to run for
Congress, complicating a Michigan race that is expected to be among the most
competitive in the nation.
The so-called "Dr. Death," who was released from prison last year and remains on
parole, will run as a candidate with no party affiliation for a congressional
seat representing Detroit's suburbs, an associate said.
"Jack is in great spirits, and he intends to do this. He just hopes for some
honesty in government," said Ruth Holmes, Kevorkian's longtime jury consultant.
Kevorkian plans to focus on prison reform and bringing integrity to the
government, Holmes said. She said the retired pathologist was not available for
an interview and would make a formal announcement next week.
Kevorkian told The Oakland Press of Pontiac, Mich., which first reported his
plans on Wednesday, that his campaign was in a "formative stage" and that he was
running because "we need some honesty and sincerity instead of corrupt
government in Washington."
Holmes said Kevorkian would need to collect 3,000 signatures by mid-July to be
placed on the ballot. "That will be very easy for Jack," she predicted.
The Oakland County seat currently is held by Republican Rep. Joe Knollenberg,
who is being challenged by Democrat Gary Peters, a former state lottery
commissioner who has been highly touted by national party leaders.
Knollenberg, who first was elected in 1992, defeated Democrat Nancy Skinner in
2006 with 51.5 percent of the vote despite outspending her by about 7-to-1.
Democrats have targeted the seat.
Both campaigns downplayed Kevorkian's potential role in the race.
Mike Brownfield, Knollenberg's campaign manager, said Kevorkian's campaign
"doesn't affect Joe Knollenberg at all. He's going to keep getting things done
for Oakland County's families."
Peters spokeswoman Julie Petrick said "anybody has the right to run" but said
their campaign was "one of the top races in the country as far as viability and
our ability to win here."
While serving in the state Senate, Peters proposed legislation to allow voters
to decide whether to make physician-assisted suicide legal for terminally ill
patients. The ballot proposal was rejected in 1998, the same year Michigan's law
banning assisted suicide took effect.
Oakland County Prosecutor Dave Gorcyca, whose office was responsible for sending
Kevorkian to prison, said it was "probably more of a publicity stunt."
"To call attention to himself is standard protocol for Jack when he doesn't have
the limelight focused on him. I would not consider his candidacy to be a
legitimate one," said Gorcyca.
But Craig Ruff, a senior policy fellow at the Lansing, Mich.-based Public Sector
Consultants, said Kevorkian "could play the Nader in this district, denying
Peters the seat."
Ruff referenced the 2000 campaign of Ralph Nader, whom many Democrats consider a
spoiler for siphoning votes from Al Gore in his razor-thin loss to George W.
Bush in Florida.
Ruff said few Republicans would support Kevorkian because of his views on
euthanasia but predicted he could pick up a few thousand votes from some
Democrats and independents, enough to potentially affect the outcome.
Kevorkian, 79, claims to have helped at least 130 people die from 1990 until
1998 - the year he was charged in the death of Thomas Youk, a 52-year-old
Oakland County man with Lou Gehrig's disease. Kevorkian has promised not to help
in any other assisted suicides and could go back to prison if he did.
He was released from prison in June 2007 after serving the minimum of his 10- to
25-year sentence for second-degree murder in Youk's death. He spent eight years
and 2 1/2 months behind bars after earning time off for good behavior.
To serve in Congress, the Constitution requires someone to be 25 years old, a
U.S. citizen for seven years and to reside in the state they would represent,
but it does not prevent a convicted felon from seeking office.
House ethics rules say members who have been convicted of a crime while in
office that leads to at least a 2-year sentence should not vote or participate
in committee work. But it says a lawmaker's privileges are reinstated if the
member is found innocent or re-elected after the conviction.
Kelly Chesney, a spokeswoman for the Michigan secretary of state's office, said
state election law only governs legislative and state offices and there is
nothing that would prevent Kevorkian from running for federal office.
Michigan allows convicted felons to vote once they've served their sentence.
http://ap.google.com/article/ALeqM5iAexFcyuazKBCPetFNp2gfHxHdsgD8VC4A200
Peace and Love
(`'·.¸(`'·.¸ ¸.·'´) ¸.·'´)
«´¨ *Pam* ¨`»
(¸.·'´(¸.·'´ `'·.¸)`' ·.¸)
¸.·´
( `·.¸
`·.¸ )
¸.·)´
(.·´
`*.
*.
Mahatma Gandhi put it well: "Be the change you want to see in the
world." It always begins with one person.

Blue Foundation grant to fund hepatitis care

2008-07-31 05:15:31

Blue Foundation grant to fund hepatitis care
March 13, 2008 8:45 AM ET
Blue Foundation for a Healthy Florida, Blue Cross and Blue Shield of Florida's
philanthropic affiliate, announced it would give $100,000 to the Center for
Drug-Free-Living.
The grant will fund the Hepatitis Care Network of Central Florida, which will
provide free viral hepatitis prevention and treatment services to the uninsured
and underserved in Central Florida.
http://news.moneycentral.msn.com/provider/providerarticle.aspx?feed=ACBJ&date=20\
080313&id=8332141

Lawmakers Want to Hear From Victims of Hep C Scare

2008-07-31 02:34:12

Lawmakers Want to Hear From Victims of Hep C Scare
A legislative committee wants to hear from Nevadans who have been affected by
the hepatitis C outbreak caused by local medical clinics reusing medication
vials and syringes.
The Legislative Committee on Health Care will meet on Monday, March 24 at 5:30
p.m. at the Grant Sawyer State Office building at 555 E. Washington Ave. to hear
public input.
"We want those affected by this situation to have a real opportunity to provide
input regarding the steps we need to take now to make sure this horrible
situation never happens again," said Sheila Leslie, (D) Reno.
Leslie says her committee will be looking at regulatory reform, including the
frequency of inspections, and the ability to act quickly in cases of major
infractions.
http://www.lasvegasnow.com/Global/story.asp?S=8013697&nav=menu102_2

Fair Foundation proudly presents our quarterly national newsletter

2008-07-30 20:39:21

Fair Foundation proudly presents our quarterly national newsletter with many
informative articles and pictures, including links to many photos of the new
members who join every few minutes for hours wherever we exhibit.
http://fairfoundation.org/news_letter/2008/01march/000newsletter.htm.
We thank you again for your enthusiastic support.
Gratefully,
Richard
Dr. Richard Darling, DDS
President and CEO: The FAIR Foundation
Founder: The FAIR Foundation Liver Disease & Transplant Support Group
Author: Coma Life
Address: 78629 Bougainvillea Drive, Palm Desert, CA 92211
Disease
2007 NIH
Research $
Deaths
Per Disease
$ Per Patient
Death
$ Per Patient
HIV/AIDS
2.9 Billion
16,316
$ 178,046
$ 3,052
Cardiovascular Dis.
2.3 Billion
871,500
$ 2,639
$ 29
Diabetes
1 Billion
73,965
$ 14,236
$ 50
Alzheimer's Dis.
642 Million
63,343
$ 10,182
$ 143
Prostate Cancer
373 Million
27,350
$ 13,638
$ 192
Parkinson's Dis.
205 Million
17,898
$ 12,403
$ 148
Hepatitis C
121 Million
12,000
$ 10,166
$ 25
Hepatitis B
36 Million
5,000
$ 6,600
$ 32
COPD**
66 Million
126,128
$ 500
$ 5
Breast Cancer
716 Million
40,910
$ 17,501
$ 3,967
All Cancers
5.5 Billion
559,650
$ 9,888
$ 3,830
West Nile Virus
63 Million
161
$ 390,304
$ 14,932
** COPD = Chronic Obstructive Pulmonary Disease

Vertex Pharmaceuticals and Tibotec Announce Start of Phase 3 'ADVANCE' Study with Telaprevir in Treatment-Naive, Genotype 1 HCV Patients

2008-07-30 15:50:42

Vertex Pharmaceuticals and Tibotec Announce Start of Phase 3 'ADVANCE' Study
with Telaprevir in Treatment-Naive, Genotype 1 HCV Patients
Thursday March 13, 8:00 am ET
- First hepatitis C protease inhibitor to begin Phase 3 clinical development -
- Trial designed to confirm potential of telaprevir to increase sustained viral
response (SVR) rates with 24-week treatment duration -
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq:
VRTX - News) and Tibotec today announced that patient screening has begun in the
ADVANCE study, a pivotal Phase 3 clinical study with the hepatitis C virus (HCV)
protease inhibitor telaprevir in combination therapy for treatment-naïve
patients with chronic HCV infection. Telaprevir is the most advanced HCV
protease inhibitor in clinical development targeting treatment of hepatitis C, a
disease that afflicts more than 3 million people in the United States alone, and
170 million worldwide. The ADVANCE trial will enroll 1,050 treatment-naïve
genotype 1 HCV patients and will evaluate two 24-week telaprevir-based regimens
in comparison to a 48-week control arm. The primary endpoint of the study is
sustained viral response (SVR), defined as undetectable HCV RNA (<10 IU/mL) 24
weeks after the completion of treatment. In this study, rapid viral response
(RVR) criteria will be used to determine which telaprevir patients can stop all
treatment at 24 weeks.
"This is the first Phase 3 study conducted to evaluate whether an
investigational medicine for HCV may be able to both increase the rate of
sustained viral response and shorten the duration of therapy to 24 weeks in
patients with genotype 1 HCV infection compared to current treatment of 48
weeks. This is important given the expectation that approximately 40 to 50
percent of people with genotype 1 HCV who undergo treatment with current
therapies achieve SVR," said John McHutchison, M.D., Associate Director, Duke
Clinical Research Institute and a principal investigator for the ADVANCE study.
"We're interested to see whether this trial will confirm the encouraging results
seen thus far in Phase 2 studies of telaprevir. This study is another important
step forward in the evaluation of novel medicines for the treatment of HCV."
"Following discussions with the U.S. FDA in January, we have been able to
rapidly finalize the Phase 3 pivotal trial protocol and begin patient screening
at the first sites," said John Alam, M.D., Executive Vice President, Medicines
Development and Chief Medical Officer of Vertex. "The initiation of the ADVANCE
trial underscores our commitment to evaluating the potential for telaprevir to
address significant unmet medical needs in HCV."
The ADVANCE Study
The ADVANCE study (A New Direction in HCV Care: A Study of Treatment-Naive
Hepatitis C Patients with telaprevir) will be conducted at more than 100 centers
in the U.S., E.U. and certain other countries. Patient recruitment is being
initiated in the U.S., while sites in other countries will start recruitment as
national Clinical Trial Applications (CTAs) for each country are approved. The
study arms will include:
a.. 24 weeks of therapy, with telaprevir dosed at 750 mg every eight hours
(q8h) for 12 weeks in combination with standard doses of pegylated interferon
alfa-2a (peg-IFN) and ribavirin (RBV) for 12 weeks, then continuing for another
12 weeks with peg-IFN and RBV alone;
b.. 24 weeks of therapy, with telaprevir dosed at 750 mg every eight hours
(q8h) for 8 weeks in combination with standard doses of peg-IFN and RBV for 8
weeks, then continuing for another 16 weeks with peg-IFN and RBV alone; and
c.. A control arm with standard doses of peg-IFN and RBV dosed for 48 weeks.
Patients in both telaprevir arms who achieve RVR, defined in this study as
undetectable (less than 10 IU/mL) HCV RNA levels by the end of week 4, and who
stay undetectable at week 12 will receive 24 weeks of treatment. Patients in
these treatment arms who do not meet these RVR criteria but are undetectable at
week 24 will continue on peg-IFN and RBV for a total duration of 48 weeks.
Updates on the status of Vertex and Tibotec's clinical trials of telaprevir are
available at www.clinicaltrials.gov.
About Telaprevir
Telaprevir (VX-950) is an investigational oral inhibitor of HCV protease, an
enzyme essential for viral replication, and is one of the most advanced
investigational antiviral agents in development that specifically targets HCV.
The types of adverse events that have been commonly observed with peg-IFN and
RBV were seen across all treatment arms in Phase 2b trials of telaprevir. The
most common adverse events, regardless of treatment assignment, were fatigue,
rash, headache and nausea, with rash being the most common reason for treatment
discontinuation. Gastrointestinal disorders, skin adverse events (rash,
pruritus) and anemia were more common in the telaprevir arms compared to the
control arm over the dosing period.
About Hepatitis C
Hepatitis C is a liver disease caused by the hepatitis C virus, which is found
in the blood of people with the disease. HCV, a serious public health concern
affecting 3.4 million individuals in the United States, is spread through direct
contact with the blood of infected people. Though many people with HCV infection
may not experience symptoms, others may have symptoms such as jaundice,
abdominal pain, fatigue and fever. Chronic HCV significantly increases a
person's risk for developing long-term infection, chronic liver disease,
cirrhosis or death. The burden of liver disease associated with HCV infection is
increasing, and current therapies typically provide sustained benefit in less
than half of patients with genotype 1 HCV, the most common strain of the virus.
About Vertex
Vertex Pharmaceuticals Incorporated is a global biotechnology company committed
to the discovery and development of breakthrough small molecule drugs for
serious diseases. The Company's strategy is to commercialize its products both
independently and in collaboration with major pharmaceutical companies. Vertex's
product pipeline is focused on viral diseases, inflammation, autoimmune
diseases, cancer, pain and bacterial infection. Vertex co-discovered the HIV
protease inhibitor, Lexiva, with GlaxoSmithKline.
Disclosure: Dr. McHutchison receives research support, as does the Duke Clinical
Research Institute, from Vertex, and he has served in an advisory capacity for
the company.
Lexiva is a registered trademark of the GlaxoSmithKline group of companies.
Safe Harbor Statement
This press release contains forward-looking statements, including statements (i)
that the ADVANCE Phase 3 clinical trial will evaluate whether an investigational
medicine for HCV may be able to increase the rate of SVR and shorten the
duration of therapy to 24 weeks in patients with genotype 1 HCV; (ii) regarding
the possibility that the ADVANCE Phase 3 clinical trial will confirm the
encouraging results seen thus far in Phase 2 studies of telaprevir; (iii)
regarding our commitment to evaluating the potential for telaprevir to address
significant unmet medical needs in HCV; (iv) that the ADVANCE clinical trial is
a pivotal trial that will enroll 1,050 patients; (v) about the design of the
treatment arms and control arm of the ADVANCE clinical trial and the manner in
which rapid viral response criteria will be used to determine which telaprevir
patients can stop all treatment after 24 weeks; (vi) that the ADVANCE clinical
trial is another important step forward in the evaluation of novel medicines for
the treatment of HCV and (vii) our expectations regarding the number and
location of the sites for the ADVANCE clinical trial and our ability to obtain
approval to commence screening in foreign countries. While we believe the
forward-looking statements contained in this press release are accurate, there
are a number of factors that could cause actual events or results to differ
materially from those indicated by such forward-looking statements. Those risks
and uncertainties include, among other things, that the outcomes for each of our
ongoing or planned clinical trials and in particular the ADVANCE clinical trial
may not be favorable or may not confirm results from earlier clinical trials,
that there may be varying interpretations of data produced by one or more of our
clinical trials, that enrollment in the ADVANCE clinical trial may be more
difficult or slower than we currently anticipate and other risks listed under
Risk Factors in our annual report on Form 10-K, which was filed with the
Securities and Exchange Commission on February 11, 2008. We disclaim any
obligation to update the information contained in this press release as new
information becomes available.
(VRTX - GEN)
Contact:
Vertex Pharmaceuticals Incorporated
Michael Partridge, 617-444-6108
Senior Director, Strategic Communications
or
Lora Pike, 617-444-6755
Manager, Investor Relations
or
Patricia Farrell, 617-444-6533
Director, Public Relations

Very interesting! Hep C Discussion Point

2008-07-30 10:34:39

Hep C Discussion PointT is a tool designed by medical experts that takes you
through a series of questions about your hepatitis C experience. Once you've
completed the questions, the program generates a customized list of topics you
can print out and use as a guide in talking with your doctor about your
hepatitis C health care.
http://www.hepcchallenge.org/discussionpoint/index.php
a.. Answer each question to the best of your ability.
b.. Use the Next link to go to the next question.
c.. Use the Back link to review a previous question and answer.
d.. Do not use your browser's "Back" button.
e.. To receive a Hep C Discussion PointT printout, you must complete all of
the questions.
Words highlighted in Yellow can be clicked to see their definition.
Once you've completed the questions, a Hep C Discussion PointT printout will be
generated. The printout can be downloaded to your computer to save and print.
If you close your session without completing the questions and return later, you
will have to start the questionnaire over again and re-enter your information to
generate a printout. This is done to protect your privacy.
You are welcome to come back and use the tool as often as you would like.

Egypt's organ donors: Looking within for wealth

2008-07-29 23:04:29

Egypt's organ donors: Looking within for wealth
*Ahmed Abdel Halim takes a tea break in a Cairo cafe. He was a fishmonger with a
load of debt when he tried to sell part of himself. Halim's liver was unusable,
so he became an organ broker instead*
A thriving black market exists to match those in need of money with those in
need of a transplant.
By Jeffrey Fleishman and Noha El-Hennawy, Los Angeles Times Staff Writers
March 13, 2008
CAIRO -- He sits quietly at the corner cafe, a gold watch flickering on his
wrist. If you need a liver, or want to sell a piece of yours, grab a chair and
get acquainted with Mustafa Hamed, a 24-year-old ex-bus driver who fell
unexpectedly into a life as a broker in human organs.
Hamed's 4-year-old son, Mohamed, was dying of cancer and needed an artery
transplant that cost $5,000. The only savings Hamed had was what he fished from
his pockets at the end of the day.
There was another way, one whispered about for those with nothing. A man could
wager part of himself, slip into a hospital gown, and wake up with an incision
above the gut.
Hamed sold a section of his liver for a bit more than the price of his son's
operation. The boy died in surgery.
With his scar healing and his son buried, Hamed, whose knowledge of anatomy
would perhaps fill a single page, decided that driving a bus was not the fate of
the man he wanted to be. He brokered his first liver deal four months ago. He
earned $900. Four more sales have followed.
"Things shouldn't be this way, but they are," he says. "I sold part of my liver
to save my son. I had to do it. . . . You cut your body and sell your pieces.
But some people who come to me aren't that desperate. They could find other
solutions. Many men I see now want to sell their organs so they can afford to
buy an apartment to get married. That doesn't seem desperate enough to me. I try
to tell them: 'Be patient. You don't need to do this.' "
Patience and desperation move in curious currents in Cairo. Nearly half of
Egyptians live in poverty, and although the nation's economy is privatizing and
growing, inflation is crushing the poor and working class. The price of green
peppers has risen 90% in the last year.
Thousands have moved to the richer Persian Gulf; many have put off marriage, a
delay that in Egypt is the stinging sign of a man's failure. Others, such as
Hamed, have bartered kidneys and livers to pay off debts and reinvent dreams.
Similar tales echo around the globe. Human organs are brokered from Pakistan to
China; kidney-theft rings have swept through villages in India. The poor in
underdeveloped nations, such as Moldova and the Philippines, are offered
"transplant tourism" packages that arrange for them to travel to another country
and sell their organs to rich patients. It is a market of desperation and
ingenuity in which doctors ask few questions and donors often end up ill, and
sometimes dead.
The business has thrived for years in Egypt. The country has no laws and little
oversight regarding most transplants. Statistics are unreliable. Medical groups
estimate that as many as 500 unlicensed kidney transplants are performed each
year, but a legislator investigating the practice indicated that the actual
number is much higher.
Donors and patients in Cairo know where to go. There are cafes near clinics and
labs where the brokers sit, stirring tea and smoking, cellphones buzzing like
insects on the tables.
Those needing organs are easy to spot. They carry X-rays and blood work charts
under their arms. Some are ashen, some drawn; they need what they need quickly.
They come from Upper Egypt and the Nile Delta, their purses and wallets bulky
with borrowed money, and if they're lucky enough they'll be able to hire the
Japanese transplant surgeon who flies in once a month.
"My doctor told me to come to this place," says an agricultural engineer from
Upper Egypt who was shopping for a kidney near a lab in Cairo's Dokki
neighborhood, where horse carts clatter and puffed bread cools in the breeze.
He will not give his name as he straightens his pressed tunic. "I'm 58 years
old. I'm in renal failure and I have no children. I need a donor. Kidneys sell
for between 20,000 and 40,000 pounds [about $3,600 to $7,300]. I'm bargaining,
but I can't pay more than 30,000 pounds."
The donors face hardships of their own. Ayman Abdullah was an accountant in
Upper Egypt when he and his brother decided to take their parents' savings and
move to Cairo to open a cellphone shop. In a nation that's mostly desert, Cairo
is a gritty, crowded neon promise of minarets and high-rise banks that attracts
those willing to risk what little they have. Others who had left Abdullah's
village had made a fortune in the city, or so went the stories that trickled
back home.
Abdullah and his brother trusted a man -- he called himself a partner -- more
than they should have. The man vanished with the money, and suddenly the
brothers were 75,000 pounds, or about $13,700, in debt.
"I have two choices: Pay my debts or go to jail," says Abdullah, a heavyset man
in a sweater, who sits in a cafe hoping to negotiate part of his liver for
40,000 pounds. "I can't find any other solution. It's either the operation or I
lose my freedom. . . . I started looking for ads where kidney patients look for
donors, but I realized that the maximum amount of money I could get for a kidney
is 20,000 pounds. Then in the same newspaper, I found an ad by a liver patient."
Abdullah's brother found a buyer whose blood type and tissue type match his.
Abdullah says it's funny in a way -- back home he and his brother never earned
enough to be rich, but they made just enough to imagine they could be. But now,
he just wants to creep away from the shame of being made a fool.
"If God allows me to live after the operation, I won't stay in this country. I
want to go work as a schoolteacher or salesman or do any kind of job in any gulf
country," Abdullah says. "After one undergoes this operation, he feels inferior
to the rest of his people. I want to go somewhere with new people. I want people
who don't know anything about me."
Mohamed Queita, a member of the Egyptian parliament and the ruling National
Democratic Party, has been working for 12 years to pass a law to regulate organ
transplants and stop an expanding black market that draws patients from across
the Middle East and as far away as Europe.
"It's the worst kind of business in Egypt. It's worse than slavery," says
Queita, who has no comprehensive statistics but notes that one Cairo clinic had
a waiting list of 1,500 people willing to sell their organs. "I don't want the
poor turned into spare parts for the rich. . . . People are coming from all over
to buy organs in Egypt. They're mainly gulf Arabs. If you're a rich man from the
gulf, you go to a private Egyptian hospital that has contacts with organ
brokers. Serious cases of poverty in this country are causing an increase in the
theft and sale of organs."
Queita's bill proposes that transplants be limited to family members or to
donors who accept no money. The legislation has been stalled by disagreements
between Islamic clerics and doctors. Physicians support the harvesting of organs
from patients who are clinically brain-dead, but clerics regard the practice as
haram (forbidden).
The issue is a strand in a legal and spiritual debate over the definition of
death that dates to Pharaonic times. Most clerics agree with Queita that the
selling of body parts violates Islamic law.
"But there's no punishment," the lawmaker says. "Nobody goes to jail."
Ahmed Abdel Halim was a fishmonger with a load of debt when he tried to sell
part of himself. Creditors were closing in, but the lab told Halim his liver was
laced with fat and unusable. So he became a broker instead.
He says clerics advised him that his new job did not violate Islamic tenets as
long as he didn't negotiate price. He must accept what is offered. His first
commission earned him $900.
"I used to go to popular neighborhoods where young men have [financial]
problems," says Halim, who sits, dressed in a windbreaker, as a waiter hurries
by. "I'd spend time in a cafe for a few days until customers got to know me,
trust me and started to talk with me. After the person would tell me about his
problems, I'd suggest that he do the procedure. Some used to get frightened and
walk away; others used to accept and started to ask me questions about the
details of the operation."
He has brokered 45 deals over five years. The money is good, but his wife views
him as a mercenary, a man who has made a moral gray area out of his religion. To
please her, he says, he stopped brokering for a time. But he could never make it
as a fishmonger and returned to the organ business.
"I am an intermediary," he says. "I care about the donor's interest and I
guarantee the obligations of each, the donor and the patient, because they don't
know each other and have no mutual trust."
Mustafa Hamed feels much the same way. He was 11 when his father taught him
leather craft. He quit school. He tanned hides until his hands were stained, but
the most he ever earned was 30 pounds, or about $5.50, a day. He found a job
driving a bus, but he was illiterate and didn't take the test for his license,
so things got risky. He tenses a bit when he talks about his son; his fingers
press together in his lap; he looks down.
The money he was paid for a piece of his liver is gone, but he says he's been
building up a reputation in the organ business. People call him. One day he
might buy his own bus, or open a cellphone shop. His sneakers are dusty, but he
keeps his shoulders straight in his suit jacket. He sees himself as a man of
consequence.
"On the eve of my operation, I stayed in my room reading the Koran," he says. "I
was afraid, but not to the extent of changing my mind. Even if something bad had
happened to me during the operation, I would not have minded as long as the
objective was to rescue my son. If one dies for the sake of his son, he gets
rewarded by God."
jeffrey.fleishman@...
http://www.latimes.com/news/nationworld/world/la-fg-organs13mar13,0,7142627.stor\
y

"No Tears"

2008-07-29 20:22:25

Has anyone heard of this miniseries or know what TVO is or how we might be able
to watch it in the U.S.? Any info appreciated. Looks interesting!
"No Tears" (2002) (mini)
Director:
Stephen Burke
Writer:
Brian Phelan (writer)
Release Date:
14 January 2002 (Ireland) more
Plot Outline:
A drama based on the Irish bloodbank scandal of the 1990s, where it was
discovered that women treated with the blood product Anti D in the Seventies had
been contaminated with Hepatitis C.
Awards:
3 wins & 1 nomination
http://www.imdb.com/title/tt0306366/
http://www.tvo.org/TVO/WebObjects/TVO.woa?b?1004271205456400000
No Tears
Academy Award Winner Brenda Fricker (My Left Foot) stars in No
Tears a gripping, deeply moving drama about a group of ordinary women who
discover they are infected with Hepatitis C from a contaminated blood product.
Obstructed by the medical authorities and dismissed by the politicians, these
not so ordinary women take on the establishment. They form a campaign group to
reveal how and why they were infected. Their fight for truth and justice is
nothing less than inspiring. No Tears is based on a true story that rocked
Ireland in the 1990's and had parallels in Britain, France, Italy, Canada the US
and Japan. Starring Brenda Fricker (My Left Foot), Maria Doyle Kennedy (The
Commitments) and Tina Kellegher (Ballykissangel, The Snapper). From the Emmy
Award winning producers of Dirty Tricks, The Hanging Gate and Relative
Strangers.
Part 1 of 4
Episode After years of unexplained painful suffering and tiredness,
Kitty (Brenda Fricker) hear a news item on Morning Ireland that links hepatitis
C to a blood product she was given two decades before to protect her unborn
child.
Info
Past Episodes
On Air Thursday, March 13 at 9:00 PM
This show repeats on: Friday, March 14 at 12:00 AM

St. Vincent's Hepatitis C Support Group Meeting NY NY

2008-07-29 15:28:22

St. Vincent's Hepatitis C Support Group Meeting
Tuesday, March 18th, at 6 PM
St. Vincent's Hospital, New York, NY
170 West 12th Street (off 7th Ave, SE Corner)
Coleman Building, Room 1249
This meeting is open to anyone impacted by or interested in Hepatitis C. That
includes healthcare professionals, patients, care providers, family etc.
We meet the third Tuesday of each month. Our next meeting will be March 18th at
6 PM.
It's been established that a strong social support helps people dealing with a
difficult condition. Come join us to add to your support system. We try to offer
education, information, a shoulder with a network and lest I
forget---refreshments!
The doctors at St. Vincent's have made a commitment to our support group to try
to have one of their staff attend our meetings. This is in an effort to offer us
medical information and guidance and in return they develop a better
understanding of how Hepatitis C impacts us as patients.
Last month we had the good fortune to have Dr. Robilotti, the head of St.
Vincent's Gastro Dept. attend our meeting. I believe we all felt we benefited
from his presence.
Refreshments will be provided courtesy of Melanie Huml, Peg-Intron Rep for
ScheringPlough Pharmaceuticals, she will be available at the beginning of the
meeting.
The facilitator of this meeting is Lillian de Mauro, she can be reached at
lilliandem@...

Re: Unbelievable

2008-07-29 08:29:15

Pam, really unbelievable that a woman would be locked in a bathroom for
two years. You are right; is it a joke or is it mental illness. I
would say a hard core case of agoraphobia and a need to sit somewhere!
Oh boy, the folks we don't know of but hear of in this crazed world of
ours! lol
Peace, Love,
Debbie

Tech professor searches for hepatitis vaccine

2008-07-29 03:14:51

Tech professor searches for hepatitis vaccine
X.J. Meng has received several accolades recently, including nearly $3 million
in grants.
Greg Esposito
BLACKSBURG -- For X.J. Meng, 2008 has been a very good year.
A professor of virology in the Virginia-Maryland Regional College of Veterinary
Medicine's department of biomedical sciences and pathobiology at Virginia Tech,
he's received one major accolade after another the past couple of months.
In January, he was recognized by academic publisher Thomson Scientific as
belonging to the top 1 percent of the most-frequently cited scientists in the
world in the past decade in two fields -- microbiology and clinical medicine. In
February, he was awarded nearly $3 million in grants from the National
Institutes of Health to study the hepatitis E virus with the goal of eventually
developing a vaccine to protect people and animals from it. And earlier this
month, Meng received word that he will receive an award for research excellence
from the Lumina Foundation.
Born and raised in China, Meng received medical degrees and practiced medicine
there before coming to the United States in 1991 to receive a doctorate in
immunobiology at Iowa State University's college of veterinary medicine.
Four years later he took a position with the National Institutes of Health in
Bethesda, Md., and he joined the faculty at Tech in 1999.
Gerhardt Schurig, dean of the veterinary school, referred to Meng as the
college's "star researcher" and said Meng's success has attracted the funding
and attention to allow the school to build a nucleus of virologists. Meng was
the school's only virologist until they hired three more this past year.
"X.J. is the engine, to some extent, for the whole virology team," he said.
Meng credits much of his success to his dual background in human and veterinary
medicine. Several recently discovered viruses that affect humans -- such as HIV,
SARS and the hantavirus -- can be traced to animals. Whether it's animals or
humans, all medicine is connected, he said.
Though Meng didn't feel satisfied or challenged as a medical doctor in China, he
said his work treating people there has helped him see beyond the theoretical
side of research to the practical application of it. That's why the project
funded by the recent grants excites him so much. The potential to create a
vaccine to help people sometimes makes the frustrating part of research
worthwhile. Hepatitis E, while usually not fatal, is a major problem in
developing countries in Asia and Africa and in Mexico. It's also found in the
U.S.
Meng and other researchers at Tech recently discovered hepatitis E-related
viruses in pigs and birds. The grants will allow researchers, including five
other co-investigators at the vet school, to follow up on those discoveries and
look into ways to study the virus in those animals with hopes of developing a
vaccine for humans. Similar work was done with cows to create a smallpox
vaccine.
Meng first began working with swine viruses at Iowa State and his work helped
develop a vaccine for a pig virus -- Porcine Circovirus Two -- in 2006. His
research on that virus, as well as hepatitis E, is why he's been cited so much
by microbiology researchers. The clinical medicine citations are also because of
his circovirus research and work he's done on another pig virus -- Porcine
Reproductive and Respiratory Syndrome Virus.
The Thomson Scientific recognition meant a lot to Meng because, as a researcher,
that's ultimately the reason you publish. His work in the microbiology field has
been cited 896 times in the past 10 years while his clinical medicine work has
been cited 1,842 times.
"If your publication, nobody reads it, nobody cites it, it doesn't make an
impact," he said. "You can say all you want to say."
One of the reasons Meng came to Tech was that it gave him a chance to teach. He
teaches courses in virology and emerging infectious disease and will probably
teach in the new medical school in Roanoke being planned by Tech and Carilion
Clinic. While all of the research awards are great, he said he'd love to receive
one for teaching some day.
Likewise, Meng enjoys working with the staff, graduate students and postdoctoral
associates in the vet school's Center for Molecular Medicine and Infectious
Disease. Nine researchers work there and six more will be added as a result of
the grants.
"It's not just me. I'm the one directing the lab, but it's those people in the
lab," he said. "They're the ones who did the work."
http://www.roanoke.com/news/nrv/wb/154380

Hep C Handbook: A Resource Guide for Georgians is now available

2008-07-28 19:56:29

The Hep C Working Group of Georgia, a coalition of agencies dedicated to
battling hepatitis C in Georgia, is extremely pleased to announce that the
Second Edition of the Hep C Handbook, a publication written and designed
expressly for Georgians living with hepatitis C, as well as professionals who
work with Georgia's Hep C patients, is hot off the press and available now.
The first edition was published in 2005 and it proved to be an invaluable
resource to Georgians and those in the surrounding states who were battling
hepatitis C. There have been many changes since 2005 and the time was right for
an updated handbook to help those who needed it.
While not a substitute for qualified medical care from a licensed physician, the
Hep C Handbook contains extensive information to aid those affected by hepatitis
C including physician referrals, physical and mental heath, legal resources,
treatment options, transplant and financial resources information as well as
many other areas of information, all available to citizens of Georgia.
This project was a labor of love for the organizations involved in developing
this up-to-date informational resource. The Georgia Division of Public Health,
the American Liver Foundation, Atlanta Harm Reduction Center, H.E.A.L.S. of the
South, as well as our dedicated physicians and committee members all made this
dream a reality and it is through our collective effort that the second edition
of this book has come to fruition.
Appreciation goes out to those companies and organizations providing funding for
printing costs making the Hep C Handbook possible. Lead supporters were Roche
Laboratories, Valeant Pharmaceuticals, Vertex and GlaxoSmithKline. Through their
generosity we were able to print 15,000 copies of the handbook and we cannot
express our appreciation enough for their kindness.
In addition to the handbook being in print form it is also available in PDF
format on the American Liver Foundation website at:
www.liverfoundation.org/chapters/georgia and the H.E.A.L.S of the South website
at: http://www.healsofthesouth.org/Hep_C_Handbook.html.
If you are interested in receiving these books for yourself or others who are in
need, please contact:
Katherine C. Cline
Executive Director
American Liver Foundation
2250 North Druid Hills Road, Suite 285
Atlanta, GA 30329
telephone: 404-633-9169
www.liverfoundation.org/chapters/georgia
OR
Tina J. Benoit, MPH
Hepatitis C Coordinator & Surveillance
Georgia Division of Public Health/Notifiable Disease Epidemiology Section
2 Peachtree Street, NW 14-264
Atlanta, GA 30303
(404) 463- 0849 (Phone)
(404) 657- 2608 (Fax)
tbenoit@...

Unbelievable

2008-07-28 13:46:01

Unbelievable!
At first I wasn't sure whether to send this to my jokelist or my medical list!
Quite sad really.
http://www.foxnews.com/story/0,2933,337232,00.html

DA raids office of Dix Hills doc in Hep C probe

2008-07-28 08:21:29

DA raids office of Dix Hills doc in Hep C probe
BY MICHAEL AMON | michael.amon@...
March 12, 2008
The Nassau County district attorney's office raided Dr. Harvey Finkelstein's
office yesterday as part of a probe into whether the Dix Hills physician caused
two cases of hepatitis C and not one as state health authorities previously
believed, according to court records, medical documents and interviews.
Investigators seized medical records and a computer hard drive from
Finkelstein's Plainview medical office on Old Country Road yesterday morning.
Prosecutors are considering whether they can bring felony charges. They could
include second-degree assault, apparently for causing the infections, and
falsifying business records and offering a false instrument, for changing or
withholding records from the state Department of Health, according to an
affidavit for the search warrant.
Finkelstein has not been charged. His attorney, Peter Chavkin of Manhattan,
declined to comment on yesterday's search and potential charges. "We're
cooperating with the investigation in every way imaginable," he said. "At no
time has he withheld any information."
The search warrant made blanket demands for business and medical records but
also asked for specific patient charts for three hepatitis C patients who
received pain medication injections on July 15, 2004.
The first of those patients was Steve Corrado, 53, a Florida man who says he has
had hepatitis C for nearly a decade. His medical records - portions of which his
attorney gave to Newsday - show that Finkelstein knew of Corrado's diagnosis as
far back as 1999.
Two patients who received injections after Corrado - Raymond Bookstaver of
Hicksville, and a 66-year-old Syosset man - say they subsequently developed
hepatitis C. The three men's disease strains share the same genotype of 1B,
though the three have not been definitively linked genetically.
But the Health Department did not learn of Corrado's records until November and
had by then concluded that the hepatitis was passed from Bookstaver to the
Syosset man, the affidavit said. That conclusion was incorrect, said Jeffrey
Kimmel, a Manhattan attorney for both Bookstaver and Corrado.
"To me, Steve Corrado is the known hepatitis C patient who saw Finkelstein that
day and was potentially the first link in the chain of contamination," Kimmel
said.
The state Department of Health is also reviewing Corrado's medical records and
told the district attorney's office about him, said spokeswoman Claudia Hutton.
Health authorities have said they were frustrated by what they saw as
Finkelstein's reluctance to turn over records. They expanded the investigation
to more than 10,000 patients after smaller lists turned out to be incomplete.
Corrado, a former carpenter now living on disability, said he began receiving
injections from Finkelstein in the mid-1990s after a work injury left him with
debilitating back pain. In 1999, Corrado said he became ill and was diagnosed
with hepatitis C. He said he immediately called Finkelstein, with whom he had
become close.
"He told me it was probably all of the tattoos I got in the '70s," Corrado said.
In a July 20, 1999, medical document, Finkelstein notes Corrado's diagnosis:
"Hep C x 20 years."
Five years later, on July 15, 2004, in a procedure that ended at noon,
Finkelstein injected Corrado with medications and dyes. About 35 minutes later,
Bookstaver was injected with the same four medications - triamcinolone, a
steroid; lidocaine and bupivacaine, both local anesthetics; and ketorolac, an
anti-inflammatory drug, according to medical records. The Syosset man was
injected with the same at 1 p.m., records show.
How story unfolded
Key dates in the syringe mess
Nov. 13, 2007 About 630 patients of Dr. Harvey Finkelstein are notified by the
state that they are at risk for HIV and hepatitis B and C - state and county
health officials say he was reusing syringes while issuing injections. At least
one of the doctor's patients had already contracted hepatitis C.
Nov. 14 As hundreds of people begin getting the letters, controversy erupts over
the health department's decision to wait three years to begin notifying the
public - only after its investigation was complete.
Nov. 19 The probe widens. The state moves to review more than 250 records
gathered from Finkelstein's offices after authorities receive calls over the
previous week from former patients. They were not among the original 628
patients notified.
Nov. 20 Probe widens again. State moves to get records on Finkelstein patients
dating back to 1994 and urges testing for patients dating from then.
Nov. 21 Nassau district attorney's office opens investigation.
Dec. 4 Finkelstein announces he is taking a "temporary leave of absence" from
three of the hospitals and clinics where he had privileges.
Feb. 29 Sen. Hillary Rodham Clinton urges the Food and Drug Administration to
address the risk posed by multidose medicine vials.
March 11 DA's office seizes documents from Finkelstein's office.
http://www.newsday.com/news/local/suffolk/ny-lifink125610558mar12,0,7008996.stor\
y

Beaumont nurse allegedly gave 15 patients hepatitis C

2008-07-28 01:13:35

Beaumont nurse allegedly gave 15 patients hepatitis C
By Ramon Bracamontes / El Paso Times
As many as 15 patients at Beaumont Army Medical Center might have contracted
hepatitis C in 2004 allegedly from a nurse at the hospital who was arrested last
week after a federal grand jury in El Paso indicted him on assault and theft
charges, federal court records show.
Jon Dale Jones, who worked at Beaumont in 2004, was arrested Friday in Miami and
charged with three counts of assault, three counts of aggravated assault and
three counts of possessing a controlled substance.
He was released on $150,000 bond and is expected to come to El Paso to face the
federal charges. A date for the El Paso hearing has not been set.
While the indictment issued against Jones does not give details on how the 15
patients at Beaumont became infected with hepatitis C, several federal civil
lawsuits filed on behalf of the patients infected do.
According to a lawsuit filed against Beaumont and the other private companies
providing care at the hospital, Jones contracted hepatitis C while working at
the Army hospital from a patient who was having surgery. Even though Jones had
symptoms that correspond with hepatitis C, hospital officials did not test him
and they let him keep working as an anesthetist, documents state.
Jones allegedly also stole the pain killer Fentanyl and was administering it to
himself before giving it to the patients, records state.
El Paso lawyer Clark Harmonson, whose law firm, T.O. Gilstrap, filed one of the
civil lawsuits, said they are representing a 70-year-old El Paso man who was
infected after going to Beaumont for surgery.
"This was a bad deal up there," Harmonson said. "We are hoping to get justice
for our client who was wronged by Jones and William Beaumont."
Jones could not be reached for comment. He does not have an El Paso lawyer, and
his Miami lawyer could not be reached for comment.
Beaumont officials said Tuesday that they could not comment on pending
litigation.
According to the lawsuit, "after several people contracted hepatitis C at the
hospital, on October 13, 2004, the hospital contacted the Texas Department of
Health Services and Center for Disease Control and Prevention for help in
investigating two hepatitis cases."
Hepatitis C is a liver disease which is spread primarily by direct contact with
the blood of a person infected with hepatitis C.
"According to the CDC, 15 patients who had surgery at Beaumont between July 31,
2004, and October 12, 2004, developed HCV infections. The investigation found
that Jones was the only staffer who provided care for all 15, and all other
staff members tested negative for HCV," the lawsuit states.
After the CDC investigation, the FBI launched a criminal investigation which
resulted in last week's indictment.
Harmonson said that now that an indictment has been issued, they are reviewing
their options to see what civil steps can be taken next.
All of the civil lawsuits were stayed in late 2006 by U.S. District Judge Frank
Montalvo because of a possible criminal investigation, the judge's order states.
El Paso lawyer Michael Volk, who represents eight of the infected patients, said
five of his clients were active-duty soldiers who had gone to Beaumont for
treatment.
"When the judge lifts the stay, then we will proceed with the civil cases," Volk
said.
Ramon Bracamontes may be reached at rbracamontes@... ; 546-6142.
http://www.elpasotimes.com/ci_8539876?source=most_viewed

Pricey Desai dumped by hospital

2008-07-27 22:34:53

Pricey Desai dumped by hospital
Doctor agrees to cancel deal official said held UMC 'hostage'
By Tony Cook
Wed, Mar 12, 2008
University Medical Center on Tuesday canceled its contract with Dr. Dipak Desai,
whose clinic is at the center of the nation's largest hepatitis C scare.
While that means the man who oversaw unsafe medical practices that resulted in
at least six patients being infected with hepatitis C is no longer getting
taxpayer money, the history behind the lucrative contract - under which Desai
and his company received nearly $1 million a year primarily to accept referrals
from UMC to Desai's clinics - leaves lingering questions.
Those clinics - the Endoscopy Center of Southern Nevada and the Gastroenterology
Center of Nevada - are under criminal investigation. Health inspectors say nurse
anesthetists at the endoscopy clinic used syringes multiple times on patients, a
practice that could allow vials of anesthetics to become tainted with infected
blood from the first patient and then passed on to other patients.
Six patients contracted hepatitis C at the clinic and 40,000 have been notified
they should get tested for infectious diseases.
Desai, majority owner of the endoscopy clinic, has directed UMC's
gastroenterology department for years. Hospital officials say such unsafe
practices did not occur at the hospital, where standards are higher and
physicians, not nurses, administer anesthesia.
Desai scored an enormous raise for himself and his associates last year by
canceling his UMC contract midstream and then asking the hospital for a hefty
raise.
UMC spokesman Rick Plummer said that when Desai canceled his contract in March
2007, it left the hospital in a lurch. UMC solicited proposals from other
physicians to take over the work, but only Desai and another group responded.
Desai, who had been making $84,000 a year under his previous contract, and his
company asked for $1.85 million a year. The competing group, Digestive Disease
Specialists, offered to do the work for $960,000 a year, but the hospital
determined the group did not have enough physicians to cover the patient load,
Plummer said.
That left only Desai's group.
"To tell you the truth, UMC was held hostage," Plummer said.
UMC negotiated the price down to $990,000 for the first year of the contract, a
payment that would increase each year after that for an average annual cost of
$1.05 million. That's more than 12 times what Desai had been making under his
previous contract.
UMC Interim Chief Executive Kathy Silver recommended approving the deal in
October 2007. County commissioners did so on their consent agenda, a list of
dozens of items that they pass in a single vote. There was no discussion about
the contract's price tag at the commission meeting.
Plummer said the cost disparity between the old and new contracts is misleading
because the newer contract actually covered several doctors in Desai's practice
who had held separate contracts of their own to provide professional medical
services at UMC.
But even if those other contracts are added to Desai's previous deal, they total
only $210,000 annually, nowhere near the $990,000 the group was receiving until
Tuesday.
Despite the pay boost, Desai performed no procedures at UMC itself in 2007,
Plummer said. Instead, UMC referred 1,481 patients to Desai and his clinics that
year. On top of payments that Desai and his company received from UMC, they also
were allowed to bill those patients.
Plummer said UMC had to pay a provider for the service because doctors wouldn't
accept many of those patients if they lacked insurance. He said Tuesday he
didn't know how many of the patients referred to Desai and his clinics did not
have insurance.
The Sun left messages for Desai's attorneys and at his clinic, but the calls and
e-mails were not returned.
Clark County commissioners are expected to sign off on the cancellation of
Desai's contract at their March 18 meeting.
Plummer said Desai agreed to cancel the contract after being approached by the
county.
http://www.lasvegassun.com/news/2008/mar/12/pricey-desai-dumped-hospital/

Reminder about the sister site

2008-07-27 10:14:45

This is a reminder that very few people post at this site. You need to go to
the sister site at:

Expert Available to Discuss Las Vegas Clinic Hepatitis C Debacle and Future of the Disease Treatment and Prevention

2008-07-27 07:42:35

Expert Available to Discuss Las Vegas Clinic Hepatitis C Debacle and Future of
the Disease Treatment and Prevention
Newswise - The recently reported unsafe medical procedures that infected
patients with Hepatitis C at a medical clinic in Las Vegas has left thousands of
people wondering if they could be infected. Nearly forty thousand people have
visited this clinic that was found to be reusing syringes and vials of
medication for nearly four years.
For those covering health and medical news and stories related to Hepatitis C,
Samaritan Pharmaceuticals makes available their CEO, Dr. Janet Greeson.
Samaritan knows the severity of hepatitis C and is currently developing a drug
to treat the disease. "I have dedicated myself to trying to eradicate diseases,"
Dr. Greeson states. "To find out that a local clinic where numerous patients
like myself were undergoing colonoscopy testing as a precaution against colon
cancers, only to then be exposed to possible Hepatitis C infection, concerns me
greatly, to say the least."
Hepatitis C (HCV) is characterized by inflammation of the liver, usually
producing swelling and, in many cases, permanent damage to liver tissues. HCV is
one of the most common types of viral hepatitis. It can lead to long-term,
persistent infections, chronic liver disease, and in many cases, even death.
Liver failure due to HCV is the leading cause of liver transplants in the United
States.
Samaritan is working on a HCV drug, SP-30, that inhibits replication preventing
HCV from entering healthy cells. SP-30 appears to be the first true HCV
antiviral therapeutic offered for treatment of individuals infected with HCV. In
addition to its efficacy, SP-30 appears to have an extremely favorable safety
profile, and may offer the convenience of oral dosing in contrast to the
standard injectable treatments prescribed today.
Biography of Expert - Dr. Janet Greeson, Samaritan Pharmaceuticals Chairman,
President, and CEO
Dr. Janet Greeson, Chairman, President and CEO, led the bold initiative that
transformed Samaritan from a "one drug" company to an innovative "Drug
Development Pipeline" biopharmaceutical company. She strategically created a
long-term value and growth model with the Samaritan/Georgetown University
collaboration; a model she has duplicated with McGill University in Montreal,
Canada, and intends to implement in other top-tier universities as a solid
strategy to continue to build Samaritan's value and sustain its future
profitability.
Dr. Greeson is a successful healthcare professional with over two decades of
corporate experience focused on emerging growth situations, leadership
development, and mergers and acquisitions. Although she has worked with
Samaritan for eleven years, as CEO for the past six years she has demonstrated a
relentless perseverance and determination to succeed in the face of unrelenting
change. She is extremely motivated and equipped to attack problems and seize
realistic opportunities, with capability, courage and confidence.
Dr. Greeson is a co-inventor of eighteen patent applications, and presently has
nine peer-reviewed journal publications. She is a best selling author of It's
Not What You Are Eating, It's What's Eating You; and a renowned public speaker,
whose guest appearances on numerous radio and TV Talk shows, has opened the door
to tell the Samaritan story, in a concise and professional manner.
Dr. Greeson is an experienced growth "Model" developer. In the past, Dr. Greeson
developed model "Addiction Rehab Programs" for the US Navy, and went on
privately, to develop and grow a nationwide "inpatient treatment program model"
which she later sold to Columbia/HCA (NYSE:COL).
Dr. Greeson has an eclectic past, once working with Mother Theresa and was
privileged to be the U.S. Congressional Nominee for the State of Nevada in 1994,
winning the primary without spending a dollar to campaign. She currently
fulfills her altruistic energies with the Samaritan Innovative Science
Foundation.
Dr. Greeson holds a BA from Florida Technological University 1978; an MA from
Rollins College 1979; a PhD from Columbia Pacific University 1987.
Dr. Greeson serves as an expert resource on the following:
. Hepatitis C
. Antiviral therapeutics
. Infectious diseases
Dr. Greeson can address the following FAQs:
. How might clinics ensure patients against the inadvertent infection of
Hepatitis C?
. What new treatments and procedures are in the pipeline for the treatment and
prevention of Hepatitis C and other infectious diseases?
Samaritan Pharmaceuticals is a life science company focused on commercializing
its pipeline of innovative drugs to relieve the suffering of patients with
Alzheimer's, cancer, heart disease, and infectious disease. Samaritan's business
strategy is to partner drug candidates in its pipeline after Phase II (proof of
concept) human studies. Samaritan has executed its first partnering agreement
with Pharmaplaz, Ireland for its PII, HIV drug SP-01A. In addition, Samaritan's
sales arm has acquired the marketing and sales rights to sell ten
revenue-generating products in Greece and various Eastern European countries.
http://www.newswise.com/articles/view/538578/?sc=rsmn

Goodsearch

2008-07-27 03:22:48

*You can post this if you think it may help others understand how to do it.*
Instead of writing straight to Butch I thought I would take him up on his
*offer* and send this to everyone as there has only been 34 searches in the
month of March and I am fairly sure they are mostly mine! SO unless you go to
www.goodsearch.com and make sure HEALS of the South (Tallahassee, Florida) is
HELD in your charity area then you won't be goodsearching for H.E.A.L.S When
you first enter HEALS you will get a LONG list of charities and you just have to
scroll until you find HEALS of the South. Once it is placed there it will hold
it :-) Hope this helps a few of you help HEALS and thanks!

Reminder about GoodSearch please to help H.E.A.L.S!

2008-07-26 22:45:43

Reminder about GoodSearch please!
a.. Web
a.. Images
a.. Video
Please use this site honestly. Fraudulent searches will result in your charity
being delisted.
a.. WHO DO YOU GOODSEARCH FOR?
HEALS of the South (Tallahassee, FL)
Search now and money will go to your designated cause.
www.goodsearch.com and then put H.E.AL.S of the South into the search area as
above. Thanks a million!

Changing trends in hepatitis C-related mortality in the United States, 1995-2004.

2008-07-26 16:15:33

Changing trends in hepatitis C-related mortality in the United States,
1995-2004.
Wise M, Bialek S, Finelli L, Bell BP, Sorvillo F.
Department of Epidemiology, School of Public Health, University of California,
Los Angeles.
The disease burden and mortality from hepatitis C are predicted to increase in
the United States as the number of persons with long-standing chronic infection
grows. We analyzed hepatitis C mortality rates derived from US Census and
multiple-cause-of-death data for 1995-2004. Deaths were considered hepatitis
C-related if: (1) hepatitis C was the underlying cause of death, (2) chronic
liver disease was the underlying cause and hepatitis C was a contributing cause,
or (3) human immunodeficiency virus was the underlying cause and chronic liver
disease and hepatitis C were contributing causes. A total of 56,409 hepatitis
C-related deaths were identified. Mortality rates increased 123% during the
study period (1.09 per 100,000 persons to 2.44 per 100,000), but average annual
increases were smaller during 2000-2004 than 1995-1999. After peaking in 2002
(2.57 per 100,000), overall rates declined slightly, but continued to increase
among persons aged 55-64 years. Overall increases were greater among males
(144%) than females (81%) and among non-Hispanic blacks (170%) and Native
Americans (241%) compared to non-Hispanic whites (124%) and Hispanics (84%). The
7,427 hepatitis C deaths in 2004 (mean age: 55 years), corresponded to 148,611
years of potential life lost. The highest mortality rates in 2004 were observed
among males, persons aged 45-54 and 55-64 years, Hispanics, non-Hispanic blacks,
and non-Hispanic Native American/Alaska Natives. Conclusion: Overall, hepatitis
C mortality has increased substantially since 1995. Despite small declines in
recent years, rates have continued to increase among persons aged 55-64 years.
Hepatitis C is an important cause of premature mortality. (HEPATOLOGY 2008.).
PMID: 18318441 [PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/18318441

Florida medical records sold at surplus store

2008-07-26 09:16:51

Florida medical records sold at surplus store
SALT LAKE CITY (AP) -- The medical records of some Central Florida
Regional Hospital patients were sold last month at a Salt Lake City surplus
store for about $20, a newspaper reported.
"I find it inexcusable," said Susan Mezzoni, a Lake Mary, Fla., woman
whose husband's records were among those sold. "I don't like that they're out
there."
The Deseret Morning News of Salt Lake City reported in a copyright story
for Monday editions that the records of 28 patients were sold to a local school
teacher looking for scrap paper for her fourth-grade class.
The mixup is being blamed on a shipping problem, and UPS told The
Associated Press on Monday it is investigating.
The box lost its label, said Atlanta-based UPS spokesman Norman Black.
After its arrival at a vendor facility responsible for trying to determine who
owned the package, it appears a worker failed to open and catalog all the
contents properly.
"It appears the box was classified as scrap paper of no value," Black
said. "That's where we believe there was a break down in our process - if this
is what actually happened."
Some of the people whose records were sold or whose loved ones' records
were sold want answers and assurances it won't happen again.
"I'm aghast," said Marcy Lippincott, a Lake Mary attorney whose father's
records were among those lost. "I'm wondering who to sue. It's a complete
invasion of privacy. It's appalling to think your records can be out there
somewhere like that."
In December, the box was one of three shipped to a Las Vegas company for a
Medicare audit, said Kelly Ferrell, the hospital's risk manager. Hospital
officials had been tracking the box since it was reported missing in Phoenix but
did not contact the affected patients, she said.
"We worry about wrongful disclosure. That information is very personal,"
she said.
The packages were certified and sent by UPS, Ferrell said. When one of the
boxes didn't arrive, a Las Vegas auditor on Feb. 4 contacted hospital officials
who, in turn, contacted UPS two weeks later.
Officials said they're unsure how the box made its way to Utah, though the
package containing the records also had a document indicating it was sold
because the shipping company could not deliver it or find its owner.
Shipping companies often sell off packages that cannot be delivered.
Another UPS spokesman told the Deseret Moring News his company keeps packages
for at least three months before liquidating them.
"UPS has developed a very extensive and technologically advanced system
for trying to identify and locate missing packages," Dan McMackin said. "And
yes, we do inspect every shipment deemed to be overgoods. All sensitive
shipments are treated with confidentiality and disposed of properly."
But the package containing the records was eventually sold as scrap paper
at National Product Sales.
"UPS is not trying to pretend it has no responsibility here," Black said.
"This a mistake that was made at all levels in terms of handling this thing, and
we're going to get the bottom of it and see what we have to do to improve."
He would not identify the vendor.
Hospital officials said they were waiting up to eight business days to
hear from UPS before alerting patients, Ferrell said.
The records from Central Florida Regional contained detailed medical
histories, phone numbers, addresses, Social Security numbers and insurance
information.
Several of the patients whose information was lost in Salt Lake City are
dead, and some relatives said they were not concerned about the missing box.
"They're no good now," said Henry Humphrey of Sanford, Fla. His mother,
Hattie Humphrey, was a patient at the hospital in 2004. "It may contain her
(Social Security) number, but that's no good neither."
However, Kirk Torgensen, Utah's chief deputy attorney general, said the
deceased are prime targets for identity theft.
"Dead people, they're not typically looking at their credit file," he
said. "What better person to use their identity?"
Hospital spokesman Craig A. Bair said officials were in contact with the
shipping company and were looking at ways to ensure they did not have this
problem again.
"Boxes of that type are shipped like that by hospitals all over the
country all the time," he said.
---
Information from: Deseret Morning News, http://www.deseretnews.com
http://hosted.ap.org/dynamic/stories/U/UT_HOSPITAL_RECORDS_FLOL-?SITE=FLPET&SECT\
ION=HOME

Local utilities do not test water for drugs

2008-07-25 20:49:16

Local utilities do not test water for drugs
By JENNA BUZZACCO (Contact), LIAM DILLON (Contact), TOM HANSON (Contact), I.M.
STACKEL (Contact)
8:09 p.m., Monday, March 10, 2008
Representatives from Southwest Florida utility companies said Tuesday their
agencies do not test for pharmaceuticals in drinking water and are not required
to by the Florida Department of Environmental Protection.
The representatives reacted with interest to an Associated Press report released
Monday that showed trace elements of pharmaceuticals were found in drinking
water supplies around the United States, but had no concerns about the quality
of drinking water in Southwest Florida.
No one knows what levels of pharmaceuticals are in the water.
Local DEP spokesman Eli Fleishauer, who read the AP report, said the DEP has no
plans to require testing for the drugs and at the levels quoted in the story it
would require drinking "many hundreds of gallons of water a day to get a single
day's dose" of the drugs.
Fleishauer added that similar quantities of lead would be allowed under current
DEP drinking water regulations.
"In general, I think our water quality is good," Fleishauer said.
The Associated Press report states that studies have yet to determine what
effect elevated pharmaceutical levels in water supplies have on humans.
Decades before consumers even thought about the effect of excreted
pharmaceuticals in the drinking water supply, Paul Mattausch questioned it:
scientifically and as a consumer.
"I have a five-year-old grandson and I have no hesitation in having him drink
straight from the tap," said Mattausch, who is the director of Collier County's
water utility.
Mattausch, who has been in the water treatment business since 1968, said
Collier's water supply is well protected.
Though his department hasn't specifically tested for drugs in the water supply,
the county's treatment plants are well-equipped to catch and filter any
pharmaceuticals on the off chance that any slipped through.
All of the county's water comes from wells deep in the ground that are not
immediately impacted by surface water or discharge from wastewater plants, he
said. Most of the county's water has been in the ground for hundreds and
thousands of years, but still goes through treatment to either soften or
desalinize it. The process used would catch drug molecules which are "usually
very, very large and very complex," Mattausch said.
"Our water is very, very pure," Mattausch said, noting that the county tests for
contaminants deemed necessary by the U.S. Environmental Protection Agency and/or
DEP. If either agency directed him to test for pharmaceuticals, he would do so,
he said.
Patty DiPiero, a spokeswoman for Lee County Utilities, said the report's
findings are a result of technology. She said this type of in-depth testing,
looking for pharmaceutical drugs in the water, doesn't exist currently at the
state and local level.
"We don't have to test for these constituents," DiPiero said.
She said the EPA has been investigating the issue for years but this is the
beginning of these in-depth findings.
"It's so new to everyone," said DiPiero, who read the Associated Press
investigation with great interest.
Last year, a study by Mote Marine Laboratory found traces of antidepressants in
a group of juvenile bull sharks tagged in the Caloosahatchee River.
The study said nine of the 10 sharks tested positive for sertraline, the active
component in Zoloft.
DiPiero said she was unaware of the research or the study.
Naples Utility Director Bob Middleton said he planned to begin researching the
effects of prescription drugs in drinking water, after reading the Associated
Press report.
This will be the first time the city looks into this issue, Middleton said,
since the state DEP does not require testing for pharmaceuticals.
"We have never tested for things like antibiotics and Ibuprofen," Middleton
said. "It's not in the drinking water standards. If they're requiring to test
for something, then we're testing."
Middleton said he anticipates Naples City Council will ask about the city's
testing policy during the next council meeting.
On Marco Island, City Public Works Director Rony Joel said the city does not
test for pharmaceuticals in its drinking water, but is unconcerned about their
effect.
"I would surmise the impact on our community is nil," Joel said.
Marco's water supply comes from surface water from Henderson Creek in East
Naples. There is a "very remote concern" that leeching septic fields from
development along the creek could allow trace levels of pharmaceuticals to enter
the supply, Joel said. Regardless, he said, upgrades to the city's water plant,
which will increase its use of reverse osmosis technology - cited by the
Associated Press report as effective in removing pharmaceuticals - will further
minimize risk.
"If the DEP ever raises this to an issue of concern for our community, we will
be well positioned to meet that challenge," he said.
Fleishauer, the DEP spokesman, said studies on pharmaceuticals' negative effects
on fish are more definitive. He said the DEP and state legislature were looking
into quality standards that would address that issue.
---
Staff Writers Jenna Buzzacco, Liam Dillon, Ilene Stackel and Tom Hanson
contributed to this report.
http://www.naplesnews.com/news/2008/mar/10/local-water-utilities-do-not-test-dru\
gs-drinking-w/

HIV-positive gay men being infected with HCV soon after HIV; cases of HCV superinfection reported

2008-07-25 20:25:00

HIV-positive gay men being infected with HCV soon after HIV; cases of HCV
superinfection reported
Michael Carter, Tuesday, March 11, 2008
Many gay men are being infected with hepatitis C virus soon after they contract
HIV, according to a study conducted in London and published in the March 12th
edition of AIDS. The study, conducted at St Mary's Hospital, found that 7% of
gay men diagnosed with HIV at the hospital between 1999 and 2006 went on to
become infected with hepatitis C virus through sex.
A separate study published in the same edition of AIDS described two cases of
hepatitis C-superinfection in HIV-positive gay men.
Several outbreaks of sexually transmitted hepatitis C virus have been reported
in HIV-positive gay men. HIV treatment guidelines in the UK recommend that
patients should be tested for hepatitis C infection soon after their HIV is
diagnosed and at intervals after that according to their risk.
The guidelines do not, however, define what this risk is, and investigators were
concerned that this could mean that patients with recent hepatitis C infection
were going undiagnosed. The response to anti-hepatitis C treatment in patients
with HIV is approximately 66% in those who receive such treatment soon after
they are infected with hepatitis C, but only 33% in patients who receive
treatment when they have chronic hepatitis C infection.
Primary HIV infection in gay men is associated with unprotected sex and the
presence of other sexually transmitted infection such as gonorrhoea and
syphilis. As unprotected sex and sexually transmitted infections have been
implicated in the sexual transmission of hepatitis C virus, investigators at St
Mary's Hospital hypothesised that patients with primary HIV infection may be
vulnerable to infection with hepatitis C virus.
Between 1999 and 2006 a total of 155 gay men were diagnosed with primary HIV
infection at the hospital. Sexual histories were obtained from these men and
blood samples were taken every three months to monitor liver function and to
screen for hepatitis C virus.
A total of eleven men (7%) became infected with hepatitis C virus. No cases were
recorded before 2003. But in 2004, one (3%) of the 40 men with primary HIV
infection was diagnosed with hepatitis C. A total of 130 cases of primary HIV
infection in gay men were seen at the hospital in 2005 and four (3%) of these
patients were diagnosed with hepatitis C. Of the 155 gay men diagnosed with
primary HIV infection in 2006, six (4%) were also diagnosed with hepatitis C.
The median time between primary HIV infection and the detection of hepatitis C
was 23 months. Nine of the patients were diagnosed because of symptoms
suggestive of acute hepatitis C infection or because of abnormal liver function.
The remaining two patients had normal liver function, but were tested for
hepatitis C after mentioning high-risk behaviour.
Analysis of stored blood samples showed that none of the men were infected with
hepatitis at the time of primary HIV infection. All the men were infected with
the harder-to-treat hepatitis C genotypes 1a and 4. In seven of the men, HIV
viral load increased at the time of hepatitis C infection.
None of the men had used intravenous drugs, but in the three months before
infection with hepatitis C ten had used recreational drugs, eight reported
fisting and four reported sharing sex toys with casual partners.
"This study supports the enhanced surveillance of high-risk groups to identify
new hepatitis C virus cases and prevent the onward transmission of both
hepatitis C and HIV and to allow the opportunity for early treatment
intervention to enhance hepatitis C clearance rates", write the investigators.
They add, "we recommend the use of targeted sexual histories in conjunction with
regular serum ALT and directed hepatitis C virus testing."
Hepatitis C superinfection
Investigators from Paris report two cases of hepatitis C superinfection in
HIV-positive gay men whose only risk factor was unprotected sex.
The first case involved an HIV-positive man who was diagnosed with hepatitis C
virus genotype 4a in 2002. Phylogenetic analysis showed that this was part of a
cluster of sexually transmitted hepatitis C virus being transmitted amongst
HIV-positive gay men in Paris at that time. In December 2003 the patient was
also found to be infected with hepatitis C genotype 3. The man had been infected
with syphilis on numerous occasions and reported unprotected sex with multiple
anonymous partners.
The second HIV-positive patient was diagnosed with hepatitis C genotype 1a and
syphilis in 2004. He was provided with therapy for hepatitis C infection and had
an undetectable hepatitis C viral load three months after completing this
treatment.
However, six months after the completion of treatment, the patient was diagnosed
with syphilis and tests also revealed the presence of hepatitis C. Phylogenetic
analysis showed that although this infection was with hepatitis C genotype 1a,
it was distinct from the virus with which the man had originally been infected
and therefore represented superinfection rather than relapse after treatment.
Several cases of hepatitis C reinfection in HIV-positive gay men in London were
reported to the recent Conference on Retroviruses and Opportunistic Infections
in Boston.
"Hepatitis C virus/HIV-coinfected men who have sex with men with high-risk
mucosal traumatic sexual practices should be aware of sexually transmitted
hepatitis C virus superinfection", conclude the investigators.
Reference
Fox J et al. Increasing incidence of acute hepatitis C in individuals diagnosed
with primary HIV in the United Kingdom. AIDS 22: 666 - 668, 2008.
Ghosn J et al. Sexually transmitted hepatitis C virus superinfection in
HIV/hepatitis C virus-coinfected men who have sex with men. AIDS 22: 658 - 661,
2008.
http://www.aidsmap.com/en/news/B42AA0AE-389C-4B9A-842D-3A21E07737C4.asp

Caring Ambassadors Hepatitis C Program Launches Internet-Based Hep C Discussion PointTM to Assist People Living with Hepatitis C

2008-07-25 13:31:39

Mar 11, 2008 13:53 ET
Caring Ambassadors Hepatitis C Program Launches Internet-Based Hep C Discussion
PointTM to Assist People Living with Hepatitis C
VANCOUVER, WA--(Marketwire - March 11, 2008) - The Caring Ambassadors Hepatitis
C Program (CAP Hepatitis C), a national nonprofit organization, announces the
Internet release of its new interactive medical management tool, Hep C
Discussion PointT at www.HepCChallenge.org. Hep C Discussion PointT takes the
user through a guided series of questions about their hepatitis C experience.
Custom-built software analyzes the user's responses and generates a report with
information and topics specific to the user's inputs. The report is designed to
be used as both a learning tool for the patient and as a guide to facilitate
communication and enhance the health care partnership between people living with
hepatitis C and their doctors.
Hep C Discussion PointT was developed by CAP Hepatitis C in conjunction with
leading experts in the field of hepatology to help facilitate, inform, and
enhance the therapeutic decision-making process by providing discussion points
on state-of-the-art hepatitis C management. Hep C Discussion PointT is a
groundbreaking effort, and is the only tool of its kind designed exclusively for
hepatitis C clients and their health care providers.
According to Lorren Sandt, the Hepatitis C Program Director, many of the calls
CAP Hepatitis C receives are from patients who are confused by conflicting
information they read or hear about regarding hepatitis C management. "When we
designed Hep C Discussion PointT, we tried to address the most common and
relevant questions we receive from those living with hepatitis C."
"We are excited about the launch of Hep C Discussion PointT and are very pleased
to offer this tool to the hepatitis C community, which includes both patients
and their health care providers," said Dr. Tina St. John, Executive Director and
Medical Director of the Caring Ambassadors Program. "Hep C Discussion PointT
represents a new and innovative approach to CAP Hepatitis C's commitment to
ensuring that all persons living with hepatitis C have accurate and adequate
information by which to make decisions that match their personal medical
circumstances and health care goals."
Hepatitis C is the most common chronic, blood-borne viral infection in the
United States. An estimated 5 million Americans are infected with the hepatitis
C virus (HCV), the most common cause of chronic liver disease and adult liver
transplantation in the U.S. No vaccine is available to prevent chronic hepatitis
C but medications are available to clear the hepatitis C virus from the body in
up to 50% of people treated.
About Caring Ambassadors Hepatitis C Program
The Caring Ambassadors Program is a 501(c)(3) nonprofit public charity dedicated
to helping people with chronic and/or life-threatening diseases through
information/education, awareness, public advocacy, and support. Founded in 2001,
the organization is headquartered in Vancouver, Washington, U.S.A.
The Caring Ambassadors Hepatitis C Program (CAP Hepatitis C) is devoted
exclusively to meeting the needs of the hepatitis C community. The CAP Hepatitis
C mission is to improve the lives of people living with hepatitis C through
information and awareness.
For additional information about the Caring Ambassadors Hepatitis C Program and
Hep C Discussion PointT, contact Lorren Sandt at 360.816.4186 or
Lorren@....
CONTACT:
Lorren Sandt
360.816.4186
http://www.marketwire.com/mw/release.do?id=831185

Misuse of Hydrocodone-Containing Cough Suppressant Linked to Life-Threatening Adverse Events

2008-07-25 02:41:46

Misuse of Hydrocodone-Containing Cough Suppressant Linked to Life-Threatening
Adverse Events
ROCKVILLE, Md -- March 11, 2008 -- Tussionex Pennkinetic Extended-Release
Suspension, a prescription cough suppressant containing the narcotic
hydrocodone, has been linked to serious adverse events, including death, the US
Food and Drug Administration alerted today. The events are associated with the
misuse and inappropriate use of this potent cough medicine.
Tussionex contains hydrocodone and the antihistamine chlorpheniramine. The
extended-release product is approved for use in adults and children over the age
of 6 years old, and should be given no more frequently than every 12 hours.
Tussionex is contraindicated for use in patients younger than 6 years old
because of their susceptibility to life-threatening and fatal respiratory
depression.
"There is a real and serious risk for overdosing if this medication is not
used according to the labelling," said Curtis Rosebraugh, MD, MPH, Acting
Director, US FDA Office of Drug Evaluation II, Rockville, Md. "Today's action is
an example of the FDA working with drug manufacturers throughout a product's
lifecycle to keep healthcare professionals and patients informed of new safety
data."
Adverse event reports associated with Tussionex have included life-threatening
side effects and deaths in patients, including children. These reports reveal
physicians and other health professionals are sometimes prescribing, and
patients are sometimes taking, more than the recommended dose or taking the
medication more frequently than every 12 hours. The reports also show that
Tussionex is sometimes prescribed or given to children younger than 6 years old,
for whom this medication is not approved.
Highlights of the FDA's recommendations to healthcare professionals include:
· Tussionex is contraindicated in patients younger than 6 years old. FDA has
received reports of death in children younger than 6 years of age who have been
prescribed Tussionex.
· Consult the prescribing information to determine the correct dose and dosing
frequency of Tussionex. Tussionex is an extended-release formulation that should
not be prescribed at an interval less than 12 hours.
· Discuss with the patient the amount of and frequency of Tussionex to be
given. Instruct patients not to take, and parents not to administer Tussionex
more frequently than every 12 hours.
Highlights of the FDA's recommendations to patients include:
· One of the two ingredients in this long-acting cough product is hydrocodone,
a narcotic. Too much hydrocodone can cause life-threatening breathing problems
and death. Call your doctor right away if you have taken this medicine and have
trouble breathing, slow heartbeat, severe sleepiness, or cold, clammy skin.
· For Tussionex, use a medicine syringe or other device designed to measure
liquid medications. A household teaspoon or tablespoon should not be used
because the spoons vary in size and you may receive too much or too little of
the medicine. Ask your doctor or pharmacist if you are unsure how to measure the
medicine.
· If the cough is not controlled despite taking the prescribed dose at the
recommended interval, talk to your doctor.
The manufacturer of Tussionex Pennkinetic Extended-Release Suspension (UCB
Inc, Smyrna, Ga.) has agreed to update the labelling, including information that
Tussionex should not be prescribed to or used in children younger than 6 years
of age, as well as the need for accurate dosing.
For more information and the full list of the FDA's recommendations, visit
http://www.fda.gov/cder/drug/infopage/hydrocodone/default.htm
This alert does not impact short-acting cough products containing hydrocodone
that can be given every 4 to 6 hours. However, the FDA is reviewing safety
information on these other hydrocodone-containing cough products and will
provide updates as new information becomes available.
SOURCE: US Food and Drug Administration
http://www.docguide.com/news/content.nsf/news/852571020057CCF68525740900704FF7

Re: [HepCingles] info and friendship

2008-07-25 00:55:00

Hi, there...Don't be so down...I was diagnosed two years ago in June. I
was devastated, too. My shock and depression lasted 13 days. I promise
you that you'll feel better soon. I never, ever thought I'd be the
same again. But, now I'm completely back to my normal, happy self. I
hardly ever think about it. You probably feel very isolated. That was the
hardest thing for me to get through. But, that will pass, too. I hope you
have close friends and loved ones that can be with you. My best friend
stayed with me for two weeks because I just couldn't be by myself. I
got hep from getting my eyebrows tattooed back, about 8 years ago. (I'm
a strawberry blond with blond eyebrows and lashes.)
It took me only about a day after joining this "help" group that most
of these people are anything but helpful. They sit around and do
nothing but commiserate about having hep and sending each other articles
about all sorts of things that relate to having hep c. But, check it all
out and decide for yourself. I say blend back in with all your regular
friends as fast as you feel like you can. Also, another bit of good news
is that I've told a few guys I've been out with and they were okay
with it. Remember, the only way hep is transmitted sexually is if the girl
is on her period and you have a cut on your penis. It's not
tramsmitted from any other body fluid...not, saliva, not tears, not snot, not
sweat, not anything else but blood!
Like you, I'm a middle aged...okay...I'm 49 and I live in the
Baltimore, MD area. I have a God send of a doctor at Johns Hopkins. Where do
you live?
Your email was really sad. But, I hope my email has made you feel
just a smidge better.
Don't let it define who you are!
...Donna
lanardharris <lanardharris@...
of down about this disease. I join this
site to communicate with the opposite sex to sort of find a friend or
group of freinds to share my pain and hurts who dealing with the same
thing. My church family, can not reach them regarding what I am going
through. I am a single middle age man that caught hep while in
military over twenty years ago have worked for the government for 18
now on VA PENSION and tired of just sitting like waiting to be
sentence.

info and friendship

2008-07-24 22:24:59

I am new at this and sort of down about this disease. I join this
site to communicate with the opposite sex to sort of find a friend or
group of freinds to share my pain and hurts who dealing with the same
thing. My church family, can not reach them regarding what I am going
through. I am a single middle age man that caught hep while in
military over twenty years ago have worked for the government for 18
now on VA PENSION and tired of just sitting like waiting to be
sentence.

Transplanting too soon: Better oversight, please

2008-07-24 10:44:18

Transplanting too soon: Better oversight, please
A few things are evident from today's first installment of "Transplanting too
soon," a Trib investigation of this nation's liver-transplant protocols.
Some patients are receiving new livers before their need is critical. Some are
receiving livers they'll never need. Some of these patients would have lived
longer without the transplants. Some of the livers transplanted into these
patients are the worst available. And some of the recipients are unnecessarily
consigned to wretched lives of trying to deal with all of the problems such
livers can deliver.
But perhaps worst of all, some transplant centers are using these transplants'
still-high success rate to bolster their programs' overall success rate -- and
financial bottom lines -- in an increasingly competitive, multibillion-dollar
transplantation market. And that's ethically dubious.
That said, we harbor no illusions that organ transplantation is without risk. It
may be commonplace in the mind's eye but, indeed, the odds remain high the
something will go wrong. Think space flight and the two shuttle disasters.
But our four-month investigation raises fundamental and serious questions about
the integrity of liver transplantation protocol in this nation. And, in the
least, a good place to attempt to start restoring that integrity would be to
have outside parties with no financial stake in the outcome review these liver
transplants before they're performed.
http://www.pittsburghlive.com/x/pittsburghtrib/opinion/archive/s_556216.html

Organs for sale: a conversation in Vail

2008-07-24 06:18:23

Organs for sale: a conversation in Vail
Vail Symposium's Hot Topic series concludes tonight with a discussion about the
international market for organ transplant
The international market for organ transplant has been exploding with the
developments in science. While the global "market" seems far away, its affects
are palpable in a number of remarkable Colorado stories.
Aspen local and Olympic Snowboarding medalist, Chris Klug had a liver transplant
in 2000, just a year and a half before he won the Bronze Medal at the Park City
Olympics. Klug had a rare degenerative bile duct condition called Primary
Sclerosing Cholangitis (PSC), which required a liver transplant. He described
his life being "on hold" awaiting a donor. Finally, after being upgraded to the
critical stage of PSC, a donor was found for Klug. His surgeon was Dr. Igal Kam.
Co-founder of the American Transplant Foundation based in Colorado, Steve Farber
was looking to Turkey to find a kidney donor. When Dr. Kam described the
mafia-like state of organ harvesting in Turkey, Farber was deterred by the
ethical and safety standards of buying a kidney. Luckily, his eldest son, Gregg,
donated his kidney to his father. Farber founded the American Transplant
Foundation to tackle the tough policy issues that must be solved to eliminate
the gap between the need for organs and their supply.
Marc Prisant is the Executive Vice President and CFO of the Steadman Hawkins
Research Foundation. He donated a kidney to his older brother in August of 1996,
and both Prisants are doing extremely well.
What is the status of organ donors and organ transplant science in our world
today? Drs. Kam and Broelsh will examine this globally hot topic, providing an
overview to transplant policy, including what is happening across the world
today, what the long and short term effects of such policies are, and what
changes are on the way and opening the dialogue about transplant issues. Dr.
Broelsch is an international expert in liver transplants and performed the first
living-donor liver transplant in 1989. He resides in Germany. Dr. Kam arrived at
the University of Colorado in 1988 to rebuild their transplant program.
For more information about this event, call the Vail Symposium at 476-0954.
http://www.vaildaily.com:80/article/20080310/AE/41461437

Nurse accused of infecting Army patients with Hepatitis C

2008-07-23 23:40:21

March 10, 2008, 4:07PM
Nurse accused of infecting Army patients with Hepatitis C
By ALICIA A. CALDWELL Associated Press Writer
EL PASO, Texas - A former Army hospital employee is accused of infecting at
least three patients with Hepatitis C, federal authorities said Monday.
Jon Dale Jones, a 45-year-old former nurse anesthetist at William Beaumont Army
Medical Center at Fort Bliss, was arrested Thursday in Miami. He was indicted
last month on three counts each of assault, aggravated assault, and possession
of a controlled substance by fraud.
Jones was released from jail after posting 5 percent of his $200,000 bond.
His Miami lawyer, Edward O'Donnell, did not immediately return a phone message
seeking comment Monday.
Federal prosecutors say Jones infected at least three patients with Hepatitis C,
a blood-born disease that can lead to cirrhosis of the liver or liver cancer,
while siphoning drugs from them during surgeries at the Army hospital in 2004.
Jones, a civilian, is also accused of stealing the drug fentanyl, a powerful
pain killer often used for anesthesia, from the three patients.
It's not clear how or why he infected them.
Prosecutors charged that Jones stole the fentanyl from three patients from
August to October 2004 by getting keys from a subordinate to a locked container
that held the drugs. He is accused of assaulting the three patients by infecting
them with Hepatitis C on the same days he is accused of stealing their
medication.
During a bond hearing in federal court in Miami last week, Jones denied he was
infected with Hepatitis C.
But prosecutors told a judge there that Jones was linked to the patients by
officials at the U.S. Centers for Disease Control who identified a strain of
Hepatitis C that Jones and all three patients were allegedly infected with.
Army hospital spokesman Clarence Davis said Jones worked there from July 2004 to
June 2005. He said it was unclear if Jones was fired or resigned from his job.
Jones' alleged crimes were initially discovered by Army officials in October,
2004, Davis said, and forwarded to the FBI because he was a civilian employee.
"It is my understanding that the patients have been notified who may have been
victims," Davis said.
The Fort Bliss hospital, just outside El Paso, treats active and retired
military personnel, their dependents, and others eligible for Veterans
Administration benefits, Davis said. It is also a trauma center that accepts
some patients from the community.
http://www.chron.com/disp/story.mpl/ap/tx/5607435.html

Critics Blame Governor for Hepatitis C Exposures

2008-07-23 18:41:44

Critics Blame Governor for Hepatitis C Exposures
Reporter: Auburn Hutton
Email Address: auburn.hutton@...
Less than a week after a Las Vegas endoscopy center was shut down for unsafe
practices, Governor Jim Gibbons is facing some tough criticism.
During the 2007 legislative session, Gibbons cut ten new inspector positions
from the Bureau of Licensure and Certification budget. That's cutting roughly
one inspector out of every six.
Last week, the Vegas center was outed for allegedly infecting six people with
Hepatitis C and exposing some 40,000 patients
Some lawmakers say the Governor's decision to cut positions has jeopardized
public health. Gibbons announced his "critical concern" for the state of health
care in Nevada, but he also said, he's not the one to blame.
In response to some heated questions, Governor Gibbons told the media his
decision to cut surveyor positions has nothing to do with unsafe medical
practices.
"More money isn't the issue. Raising fees isn't the issue. What is the issue is
making sure people are well-trained and that we have the right number of people
to do inspections and we're working on that. That was my question. Well that was
my answer," said the Governor.
Gibbons says the positions are entirely funded by federal money and fees, not
the B-L-C budget he chipped away at last year.
State Health Director Mike Willden says the problem stems from an inability to
recruit and retain nurses who want to hold those jobs. He says it's not like the
highly-sought after direct care nurse position, and it pays less.
"You're delivering babies or caring for the elderly, doing immunizations,
something like that. This is largely administrative work where you are in a
quality control and oversight position, so it takes a different animal to do
something like that.", said Wilden.
Lawmakers say they plan to introduce legislation in 2009 that will largely
address the nurse shortage, as well as health statutes and codes that have been
broken. Gibbons says it's not the time to place blame or point fingers, but
rather, to look ahead.
"We are addressing this issue. We are looking speedily for a solution. We've
issued emergency regulations in regard to infection and infection controls," he
said.
The Department of Health is conducting inspections on all 50 ambulatory care
centers in Nevada this week. The visits are unannounced, but with all the media
attention, many of these centers will probably be expecting a visit, and
therefore, may also have time to prepare for it.
So far, out of the 14 inspections done in Northern Nevada, three clinics have
displayed unsafe practices. None of them have come up positive for spreading an
infectious disease.
For information on those clinics, and the latest on the Hepatitis C
investigation, go http://health.nv.gov .
http://www.kolotv.com/home/headlines/16471996.html

New Hepatitis C Advisory Council Draws Praise From Commissioner, Legislators, Advocates

2008-07-23 12:14:47

New Hepatitis C Advisory Council Draws Praise From Commissioner, Legislators,
Advocates
ALBANY, N.Y. (March 5, 2008) - Patient advocates, legislators and clinicians
joined State Health Commissioner Richard F. Daines, M.D., today to support
funding in Governor Eliot Spitzer's proposed 2008-09 Executive Budget for a new
comprehensive hepatitis C program and the creation of a Hepatitis C Advisory
Council to help guide the initiative.
Governor Spitzer's budget provides an appropriation of $1.6 million to improve
the health status of persons infected with hepatitis C and help prevent new
infections. The new Hepatitis C Advisory Council, established at the Governor's
direction, is holding its first meeting today to begin mapping out efforts to
improve prevention, detection and treatment.
Hepatitis C, a liver disease, is the most common chronic bloodborne viral
infection in the United States. An estimated 304,000 New Yorkers have been
infected with hepatitis C, including nearly 240,000 with chronic infections. Up
to 5 percent of persons with chronic hepatitis C infections die, and it is the
leading reason for liver transplants.
Hepatitis C is transmitted when the blood from an infected person enters the
body of a person who is not infected. Prior to 1992, being a blood transfusion
recipient was a major risk factor for hepatitis C infection, but advances in
blood screening has dramatically reduced new transmissions. Today, hepatitis C
is primarily transmitted through sharing needles or other drug paraphernalia
when injecting drugs, needlesticks or sharps exposures on the job, or, on rare
occasions, from an infected mother to her baby during birth.
"Hepatitis C has been a hidden epidemic," Commissioner Daines said, "We need to
start bringing hepatitis C out into the light of day and bring public health
approaches to address this public health issue. The Council is a major step in
this effort."
State Assemblyman Kenneth Zebrowski (D-Rockland), whose father died as a result
of complications related to hepatitis C, said, "This disease and those afflicted